0001528172 false 0001528172 2023-10-05 2023-10-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 5, 2023

 

 

ENDONOVO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   000-55453   45-2552528
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

6320 Canoga Avenue, 15th Floor

Woodland Hills, CA 91367

(Address of principal executive office)(Zip Code)

 

Registrant’s telephone number, including area code: (800) 489-4774

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None        

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 8.01 Other Events.

 

On October 10, 2023, the Company was advised by Evermed, its distributor in Taiwan, that the Taiwan Food and Drug Administration had granted a license to the Company’s SofPulse® device for medical use in Taiwan. The original license and a translation are included as an exhibit to this report.

 

Item 9.01 Financial Statements and Exhibits.

 

  (a) Financial Statements

 

None

 

(b) Exhibits

 

  99.1 Taiwan License and translation
  104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: October 12, 2023

 

  ENDONOVO THERAPEUTICS, INC.
   
  By: /s/ Alan Collier
    Alan Collier
    Chief Executive Officer

 

 

 

Exhibit 99.1

 

 

   

 

 

 

   

 

 

 

   

 

 

 

   

 

 

 

   

 

 

 

   

 

 

 

   

 

 

 

   

 

 

 

   

v3.23.3
Cover
Oct. 05, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 05, 2023
Entity File Number 000-55453
Entity Registrant Name ENDONOVO THERAPEUTICS, INC.
Entity Central Index Key 0001528172
Entity Tax Identification Number 45-2552528
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 6320 Canoga Avenue
Entity Address, Address Line Two 15th Floor
Entity Address, City or Town Woodland Hills
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91367
City Area Code (800)
Local Phone Number 489-4774
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Endonovo Therapeutics (PK) (USOTC:ENDV)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024 Plus de graphiques de la Bourse Endonovo Therapeutics (PK)
Endonovo Therapeutics (PK) (USOTC:ENDV)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024 Plus de graphiques de la Bourse Endonovo Therapeutics (PK)